CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-09-20
DOI
10.3389/fimmu.2018.02134
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia
- (2018) Karen L. Bride et al. BLOOD
- Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma
- (2018) Niels W. C. J. van de Donk et al. BRITISH JOURNAL OF HAEMATOLOGY
- CD38-NAD + Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response
- (2018) Shilpak Chatterjee et al. Cell Metabolism
- Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome byEx Vivo–Expanded Autologous NK Cells
- (2018) Yufeng Wang et al. CLINICAL CANCER RESEARCH
- Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells
- (2018) Bertram Bengsch et al. IMMUNITY
- Immunomodulatory effects of CD38-targeting antibodies
- (2018) Niels W.C.J. van de Donk IMMUNOLOGY LETTERS
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy
- (2018) Elena Zamagni et al. Expert Review of Hematology
- Daratumumab for the Treatment of Multiple Myeloma
- (2018) Torben Plesner et al. Frontiers in Immunology
- Abstract 1727: Antitumor activity associated with dual targeting of CD38 and programmed death-1 (PD-1) pathways in preclinical models
- (2018) Natalie A. Bezman et al. CANCER RESEARCH
- De-novo and acquired resistance to immune checkpoint targeting
- (2017) Nicholas L Syn et al. LANCET ONCOLOGY
- CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab
- (2017) Peter E. van Bommel et al. OncoImmunology
- Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
- (2016) Saad Z. Usmani et al. BLOOD
- CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
- (2016) Inger S. Nijhof et al. BLOOD
- First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis
- (2016) Taimur Sher et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance
- (2016) S. J. de Haart et al. HAEMATOLOGICA
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
- (2016) Niels W. C. J. van de Donk et al. IMMUNOLOGICAL REVIEWS
- The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking
- (2016) Marije B. Overdijk et al. JOURNAL OF IMMUNOLOGY
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates With Progression of Human Myeloma
- (2016) Alberto L Horenstein et al. MOLECULAR MEDICINE
- Targeting CD38 in Refractory Extranodal Natural Killer Cell–T-Cell Lymphoma
- (2016) Parameswaran Hari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies
- (2016) Ronald P. Taylor et al. SEMINARS IN IMMUNOLOGY
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance
- (2016) S. J. de Haart et al. HAEMATOLOGICA
- CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes
- (2016) Wei Hseun Yeap et al. Scientific Reports
- Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma
- (2015) N. W. C. J. van de Donk et al. BLOOD
- CD56brightCD16−NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+T Cell Proliferation
- (2015) Fabio Morandi et al. JOURNAL OF IMMUNOLOGY
- SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
- (2015) H Jiang et al. LEUKEMIA
- Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
- (2015) I S Nijhof et al. LEUKEMIA
- Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
- (2015) Marije B Overdijk et al. mAbs
- Complement in therapy and disease
- (2015) Joost P.M. Melis et al. MOLECULAR IMMUNOLOGY
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
- (2015) Henk M. Lokhorst et al. NEW ENGLAND JOURNAL OF MEDICINE
- NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model
- (2015) Alberto Horenstein et al. Cells
- Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib
- (2014) I. S. Nijhof et al. CLINICAL CANCER RESEARCH
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
- (2014) J. Deckert et al. CLINICAL CANCER RESEARCH
- Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide
- (2014) I. S. Nijhof et al. HAEMATOLOGICA
- Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice
- (2014) P Macor et al. LEUKEMIA
- Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer
- (2014) Saskia Meyer et al. mAbs
- Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
- (2014) C. A. Diebolder et al. SCIENCE
- Phagocytosis Dynamics Depends on Target Shape
- (2013) Debjani Paul et al. BIOPHYSICAL JOURNAL
- Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
- (2013) S. J. de Haart et al. CLINICAL CANCER RESEARCH
- A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
- (2013) James D Mellor et al. Journal of Hematology & Oncology
- Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications
- (2013) C C Bjorklund et al. LEUKEMIA
- Unknown
- (2013) Antonella Chillemi et al. MOLECULAR MEDICINE
- Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma
- (2012) P.-C. Tsai et al. CLINICAL CANCER RESEARCH
- Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
- (2011) W. Hu et al. CANCER RESEARCH
- rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia
- (2011) X. Ge et al. CLINICAL CANCER RESEARCH
- Editorial: CD38 and retinoids: a step toward a cure
- (2011) Fabio Malavasi JOURNAL OF LEUKOCYTE BIOLOGY
- Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma
- (2011) N W C J van de Donk et al. LEUKEMIA
- Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression
- (2011) Mu Hao et al. LEUKEMIA & LYMPHOMA
- The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies
- (2011) M S van der Veer et al. Blood Cancer Journal
- Effect of FCGR2A and FCGR3A variants on CLL outcome
- (2010) D. Dornan et al. BLOOD
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
- (2010) SaeGwang Park et al. CANCER CELL
- Treatment of relapsed and refractory multiple myeloma in the era of novel agents
- (2010) Niels W.C.J. van de Donk et al. CANCER TREATMENT REVIEWS
- T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody
- (2010) M. S. Braza et al. HAEMATOLOGICA
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
- (2010) M. S. van der Veer et al. HAEMATOLOGICA
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
- (2009) F. Romagne et al. BLOOD
- Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels
- (2008) M. S. Czuczman et al. CLINICAL CANCER RESEARCH
- Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma
- (2008) K Hatano et al. ONCOGENE
- Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology
- (2008) Fabio Malavasi et al. PHYSIOLOGICAL REVIEWS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now